✦ LIBER ✦

The new challenges generated by the exponential growth of adjuvant clinical trials

Book ID: 117659955
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 296 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)81273-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

THE CHALLENGE OF PATIENT ASCERTAINMENT I

THE CHALLENGE OF PATIENT ASCERTAINMENT IN CLINICAL TRIALS – NEW DATA

✍ Michael Detke; Janet Williams; Kenneth Kobath; Amy Ellis; Earl Giller; Andrew Le 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 69 KB

The changing face of Phase 1 cancer clin

The changing face of Phase 1 cancer clinical trials : New challenges in study requirements

✍ Barbara S. Craft; Razelle Kurzrock; Xiudong Lei; Roy Herbst; Scott Lippman; Siqi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

## Abstract Phase 1 studies in cancer have changed in recent years. Now, with the advent of new, less toxic, targeted agents, more patients may be candidates for new drug studies earlier in the course of their disease. It is to the advantage of the members of the oncology community to know more reg

Review of Breast Cancer Clinical Trials

Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project

✍ Newman, Lisa A.; Mamounas, Eleftherios P. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 361 KB

Recommendations for new trials of curren

Recommendations for new trials of currently available therapy by the IOIBD task force on clinical trials

✍ Massimo Campieri; Harald Goebell; Stephen Hanauer; Burt Korelitz; Karsten Laurit 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB

A controlled clinical trial comparing th

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

✍ Juan Dupont; Javier Altclas; Alejandro Lepetic; Mónica Lombardo; Vicente Vázquez 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Clinical studies in the development of n

Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design

✍ Ferry A.L.M Eskens; Jaap Verweij 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Various new specifically targeted anticancer agents such as matrixmetalloproteinase inhibitors, angiogenesis inhibitors, farnesyl transferase inhibitors, and tyrosine kinase inhibitors have been developed in recent years. These agents exert antitumor activity through specific target inhibition, and